Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

When the disease appears later in life, it is referred to as acquired hemophilia. Appropriate treatment can control hemophilia in these instances. There is a possibility that the disease can ...

When Sanofi acquired Bioverativ forecasts for BIVV001 were that it could become a $2 billion product, although the haemophilia A market has evolved in the meantime. The launch of Hemlibra ...

Haemophilia, an uncommon genetic disorder ... while factor XI resides on chromosome 4. Acquired variety, however, occurs in ...